Transmedics Group, INC Form 4 insider transactions

Nicholas Corcoran, See remarks of TransMedics Group, Inc., reported multiple transactions in common stock on July 10, 2026.

Gerardo Hernandez, Chief Financial Officer of TransMedics Group, Inc., reported multiple transactions in common stock on July 10, 2026.

Waleed H Hassanein, President & CEO and a Director of TransMedics Group, Inc., reported multiple transactions in common stock on July 10, 2026.

Thomas J. Gunderson, a Director at TransMedics Group, Inc., reported a transaction involving the sale of common stock.

Director Thomas J. Gunderson acquired 2,922 restricted stock units in TransMedics Group, Inc. as part of an equity grant.

Director Edward M. Basile acquired 2,922 restricted stock units in TransMedics Group, Inc. as part of a routine equity grant.

Director James R. Tobin acquired 2,922 restricted stock units in TransMedics Group, Inc. as part of an equity grant.

Director Edwin Kania acquired 2,922 restricted stock units in TransMedics Group, Inc. as part of an equity grant.

Senior Vice President and General Counsel Matthew S. Forsyth was granted restricted stock units and stock options by TransMedics Group, Inc.

TransMedics Group Director Stephanie Lovell reported the sale of 1,193 shares of common stock.

TransMedics Group Director David Weill exercised stock options and subsequently sold 3,571 shares of common stock.

TransMedics Group, Inc. CFO Gerardo Hernandez reported exercising stock options and selling common stock, including a 'sell to cover' transaction for tax obligations.

TransMedics Group's Senior VP, General Counsel, and Secretary, Anil P. Ranganath, sold 864 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

TransMedics Group SVP Nicholas Corcoran disposed of common stock to cover tax obligations related to restricted stock unit vesting.

TransMedics Group Director David Weill exercised stock options and immediately sold 5,000 shares of common stock under a Rule 10b5-1 plan.

TransMedics Group's CFO, Gerardo Hernandez, sold 920 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

TransMedics Group's Senior VP, General Counsel, and Secretary, Anil P. Ranganath, exercised stock options and subsequently sold an equal number of shares.

TransMedics CEO Waleed H. Hassanein purchased 8,775 shares at $114 via his revocable trust, bringing total beneficial ownership to 616,433 shares.

TransMedics Group Director Edward M. Basile exercised stock options and subsequently sold 4,142 shares of common stock for a significant profit.

TransMedics Group, Inc. CEO and Director Waleed H. Hassanein acquired over 16,800 shares of common stock through his revocable trust in early August 2025.

TransMedics Group Director Edward Basile exercised options and sold 4,143 shares of common stock for $125.51 per share under a pre-arranged 10b5-1 plan.

A TransMedics Group, Inc. executive sold a portion of their common stock to satisfy tax withholding obligations related to the vesting of restricted stock units.

TransMedics Group, Inc. Director Edward M. Basile exercised stock options and subsequently sold 5,000 shares of common stock for approximately $126.45 per share, reducing his direct beneficial ownership to 2,866 shares.

TransMedics Group, Inc. Director Edward M. Basile was granted 2,134 restricted stock units (RSUs) on May 22, 2025, increasing his total beneficial ownership to 2,866 shares.

TransMedics Group, Inc. Director Stephanie Lovell has increased her direct beneficial ownership by 2,134 shares of common stock through a restricted stock unit grant on May 22, 2025.

TransMedics Group, Inc. Director James R. Tobin has reported the acquisition of 2,134 restricted stock units (RSUs) on May 22, 2025, as part of his compensation.

TransMedics Group, Inc. Director Merilee Raines has acquired 2,134 shares of common stock in the form of restricted stock units, increasing her direct beneficial ownership to 4,059 shares.

TransMedics Group, Inc. director Thomas James Gunderson was granted 2,134 restricted stock units on May 22, 2025, increasing his beneficial ownership to 4,059 shares.

TransMedics Group, Inc. Director and 10% Owner Edwin M. Kania Jr. has reported the acquisition of 2,134 restricted stock units (RSUs) on May 22, 2025, as part of his compensation.

TransMedics Group, Inc. Director David Weill reported the acquisition of 2,134 restricted stock units and the sale of 732 shares of common stock, both occurring in May 2025.